Can-Fite BioPharma Ltd. (CANF) Press Releases https://ir.canfite.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/canfite/files/theme/images/logo-sm.png Can-Fite BioPharma Ltd. Logo Equisolve Investor Relations Suite <![CDATA[Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027]]> https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone Mon, 06 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1118/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone <![CDATA[Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease]]> https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson Wed, 01 Jul 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1117/can-fite-phase-2a-pancreatic-cancer-study-with-namodenoson <![CDATA[Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology]]> https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for Fri, 26 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1116/can-fite-secures-japanese-patent-allowance-for <![CDATA[Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson]]> https://ir.canfite.com/news-events/press-releases/detail/1115/can-fite-publishes-peer-reviewed-scientific-article Mon, 22 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1115/can-fite-publishes-peer-reviewed-scientific-article <![CDATA[Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026]]> https://ir.canfite.com/news-events/press-releases/detail/1114/can-fite-to-present-late-stage-clinical-pipeline-and Wed, 17 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1114/can-fite-to-present-late-stage-clinical-pipeline-and <![CDATA[Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism]]> https://ir.canfite.com/news-events/press-releases/detail/1113/can-fite-reports-positive-clinical-observation-in-phase-2a Tue, 02 Jun 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1113/can-fite-reports-positive-clinical-observation-in-phase-2a <![CDATA[Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market]]> https://ir.canfite.com/news-events/press-releases/detail/1112/scientific-publication-of-can-fite-and-vetbiolix-validates Mon, 18 May 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1112/scientific-publication-of-can-fite-and-vetbiolix-validates <![CDATA[Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy]]> https://ir.canfite.com/news-events/press-releases/detail/1111/following-positive-phase-2a-pancreatic-cancer-data Wed, 13 May 26 07:00:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1111/following-positive-phase-2a-pancreatic-cancer-data <![CDATA[Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months]]> https://ir.canfite.com/news-events/press-releases/detail/1110/can-fite-reports-positive-phase-2a-data-with-namodenoson-in Thu, 30 Apr 26 08:31:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1110/can-fite-reports-positive-phase-2a-data-with-namodenoson-in <![CDATA[Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026]]> https://ir.canfite.com/news-events/press-releases/detail/1109/can-fites-partner-vetbiolix-completes-enrollment-in Mon, 30 Mar 26 07:20:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1109/can-fites-partner-vetbiolix-completes-enrollment-in